APA (7th ed.) Citation

Chao, C., Gardner, I., Lin, C., Yeh, K., Lu, W., Abduljalil, K., & Ho, Y. (2025). Administration mode matters for 5‐fluorouracil therapy: Physiologically based pharmacokinetic evidence for avoidance of myelotoxicity by continuous infusion but not intravenous bolus. British journal of clinical pharmacology, 91(4), 1031-1040. https://doi.org/10.1111/bcp.16061

Chicago Style (17th ed.) Citation

Chao, Chih‐Jia, Iain Gardner, Chun‐Jung Lin, Kun‐Huei Yeh, Wan‐Chen Lu, Khaled Abduljalil, and Yunn‐Fang Ho. "Administration Mode Matters for 5‐fluorouracil Therapy: Physiologically Based Pharmacokinetic Evidence for Avoidance of Myelotoxicity by Continuous Infusion but Not Intravenous Bolus." British Journal of Clinical Pharmacology 91, no. 4 (2025): 1031-1040. https://doi.org/10.1111/bcp.16061.

MLA (9th ed.) Citation

Chao, Chih‐Jia, et al. "Administration Mode Matters for 5‐fluorouracil Therapy: Physiologically Based Pharmacokinetic Evidence for Avoidance of Myelotoxicity by Continuous Infusion but Not Intravenous Bolus." British Journal of Clinical Pharmacology, vol. 91, no. 4, 2025, pp. 1031-1040, https://doi.org/10.1111/bcp.16061.